Protara Therapeutics (TARA) Total Liabilities (2013 - 2026)
Protara Therapeutics (TARA) posted quarterly Total Liabilities of $10.7 million for Q1 2026, up 6.35% year-over-year from $10.1 million in Q1 2025, and down 17.93% quarter-over-quarter from $13.1 million in Q4 2025.
Protara Therapeutics (TARA) Total Liabilities (2013 - 2026) Analysis & Trends
Protara Therapeutics (TARA) has reported Total Liabilities for 14 consecutive years, with $10.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Liabilities rose 6.35% year-over-year to $10.7 million; the TTM figure through Mar 2026 stood at $10.7 million (up 6.35% YoY), while the FY2025 annual figure was $13.1 million, down 8.83% from the prior year.
- Total Liabilities retreated to $10.7 million in Q1 2026 per TARA's latest filing, from $13.1 million in the prior quarter.
- Across five years, Total Liabilities topped out at $14.3 million in Q4 2024 and bottomed at $9.0 million in Q1 2022.
- Historically, Total Liabilities has averaged $11.0 million across 5 years, with a median of $10.7 million in 2026.
- Annual changes were most pronounced in 2022 — Total Liabilities surged 110.43% — and 2024, when it slipped 16.4%.
- Protara Therapeutics' Total Liabilities stood at $11.2 million in 2022, then slipped by 5.12% to $10.6 million in 2023, then jumped by 34.68% to $14.3 million in 2024, then dropped by 8.83% to $13.1 million in 2025, then decreased by 17.93% to $10.7 million in 2026.
- Business Quant data shows TARA's Total Liabilities at $10.7 million in Q1 2026, $13.1 million in Q4 2025, and $12.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Protara Therapeutics | 234.56 Mn | 234.56 Mn | - | 14.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.78 Mn |
| Mar 31, 2026 | 10.72 Mn |
| Dec 31, 2025 | 13.06 Mn |
| Sep 30, 2025 | 12.35 Mn |
| Jun 30, 2025 | 12.51 Mn |
| Mar 31, 2025 | 10.08 Mn |
| Dec 31, 2024 | 14.32 Mn |
| Sep 30, 2024 | 12.30 Mn |
| Jun 30, 2024 | 9.60 Mn |
| Mar 31, 2024 | 9.73 Mn |
| Dec 31, 2023 | 10.63 Mn |
| Sep 30, 2023 | 11.51 Mn |
| Jun 30, 2023 | 9.92 Mn |
| Mar 31, 2023 | 11.64 Mn |
| Dec 31, 2022 | 11.21 Mn |
| Sep 30, 2022 | 9.41 Mn |
| Jun 30, 2022 | 9.43 Mn |
| Mar 31, 2022 | 9.02 Mn |
| Dec 31, 2021 | 10.68 Mn |
| Sep 30, 2021 | 10.29 Mn |